Federal Register Notice: FDA has determined the regulatory review period for Chiel Jedang Corp. and Walter Reed Army Institute of Research’s Ixiaro is 3,461 days for extending a patent which claims the human biological product. FDA recently approved Ixiaro (Japanese Encephalitis Virus, Vaccine Inactivated, Adsorbed) for active immunization for preventing disease caused by Japanese encephalitis virus in persons 17 years of age and older. To view this notice, click here.